Travere Therapeutics Ownership | Who Owns Travere Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Travere Therapeutics Ownership Summary


Travere Therapeutics is owned by 37.26% institutional investors, 0.76% insiders, and 61.98% retail investors. Blackrock is the largest institutional shareholder, holding 9.86% of TVTX shares. Delaware Small Cap Core I is the top mutual fund, with 4.42% of its assets in Travere Therapeutics shares.

TVTX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockTravere Therapeutics37.26%0.76%61.98%
SectorHealthcare Stocks 232.01%10.74%-142.75%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock7.64M9.86%$62.84M
Blackrock funding, inc. /de7.87M8.82%$300.69M
Armistice capital6.72M7.56%$160.70M
Vanguard group6.31M7.07%$241.08M
Janus henderson group4.06M5.22%$70.69M
Perceptive advisors3.79M4.27%$90.69M
Adage capital partners gp3.55M3.99%$84.89M
State street3.22M3.62%$76.91M
Fmr2.89M3.25%$69.17M
D. e. shaw2.28M2.93%$39.69M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Knott david m jr186.00K3.29%$7.11M
Rock springs capital management lp2.16M3.02%$51.74M
Perceptive advisors3.79M2.62%$90.69M
Armistice capital6.72M2.38%$160.70M
Eversept partners, lp1.42M2.33%$33.87M
Exome asset management156.92K2.27%$3.75M
Palisades investment partners137.77K1.99%$5.26M
Emerald advisers1.59M1.88%$60.91M
Emerald mutual fund advisers trust948.46K1.77%$36.24M
Kynam capital management, lp949.73K1.69%$22.70M

Top Buyers

HolderShares% AssetsChange
Janus henderson group4.06M0.04%4.03M
Perceptive advisors3.79M2.62%2.96M
Fmr2.89M0.00%1.83M
Wellington management group llp1.20M0.01%1.17M
Fiera capital874.05K0.11%874.05K

Top Sellers

HolderShares% AssetsChange
Macquarie group---4.98M
Viking global investors lp---2.60M
Armistice capital6.72M2.38%-2.15M
Finepoint capital lp---1.78M
Logos global management lp---1.00M

New Positions

HolderShares% AssetsChangeValue
Fiera capital874.05K0.11%874.05K$33.40M
Jane street group392.27K0.00%392.27K$14.99M
Arrowstreet capital, limited partnership328.65K0.01%328.65K$7.85M
Jump financial315.03K0.09%315.03K$7.53M
Neuberger berman group211.67K0.00%211.67K$5.06M

Sold Out

HolderChange
Twin peaks wealth advisors-1.00
Wealthspire advisors-4.00
Nelson, van denburg & campbell wealth management group-14.00
American national bank-15.00
Whittier trust-16.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025123-52.69%33,249,544-66.99%370.29%78-43.48%36-52.00%
Sep 30, 202597-54.46%31,195,759-67.08%350.31%55-52.17%27-59.09%
Jun 30, 2025221-4.74%100,360,5602.40%1120.92%115-13.53%7120.34%
Mar 31, 202511-94.74%4,535,953-95.23%50.03%5-96.12%3-94.12%
Dec 31, 2024107-42.47%35,070,340-57.58%450.40%66-30.53%23-58.93%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Delaware Small Cap Core I3.45M4.42%-21.39K
Macquarie Small Cap Core I3.36M3.77%-252.48K
State Street® SPDR® S&P® Biotech ETF2.92M3.16%-15.61K
Vanguard Total Stock Mkt Idx Inv2.82M3.06%8.01K
Aviva Investors GlConvtAbsRet I USD Acc2.20M2.88%-229.35K
Vanguard US Total Market Shares ETF2.51M2.82%-
Strategic Advisers Fidelity US TtlStk2.50M2.71%1.92M
Nomura Small Cap Core I2.44M2.65%-711.88K
iShares Russell 2000 ETF1.99M2.16%673.75K
SPDR® S&P Biotech ETF1.51M1.69%3.37K

Recent Insider Transactions


DateNameRoleActivityValue
Feb 20, 2026Dube Eric M CHIEF EXECUTIVE OFFICERSell$1.81M
Feb 17, 2026REED ELIZABETH E Chief Legal Officer and GCSell$122.12K
Feb 17, 2026REED ELIZABETH E Chief Legal Officer and GCSell$156.20K
Feb 04, 2026Inrig Jula CHIEF MEDICAL OFFICERSell$7.62K
Feb 04, 2026Inrig Jula CHIEF MEDICAL OFFICERSell$49.67K

Insider Transactions Trends


DateBuySell
2026 Q1-21
2025 Q4-12
2025 Q3-5
2025 Q2-6
2025 Q1-26

TVTX Ownership FAQ


Who Owns Travere Therapeutics?

Travere Therapeutics shareholders are primarily institutional investors at 37.26%, followed by 0.76% insiders and 61.98% retail investors. The average institutional ownership in Travere Therapeutics's industry, Biotech Stocks , is 381.47%, which Travere Therapeutics falls below.

Who owns the most shares of Travere Therapeutics?

Travere Therapeutics’s largest shareholders are Blackrock (7.64M shares, 9.86%), Blackrock funding, inc. /de (7.87M shares, 8.82%), and Armistice capital (6.72M shares, 7.56%). Together, they hold 26.24% of Travere Therapeutics’s total shares outstanding.

Does Blackrock own Travere Therapeutics?

Yes, BlackRock owns 9.86% of Travere Therapeutics, totaling 7.64M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 62.84M$. In the last quarter, BlackRock decreased its holdings by -152K shares, a -1.95% change.

Who is Travere Therapeutics’s biggest shareholder by percentage of total assets invested?

Knott david m jr is Travere Therapeutics’s biggest shareholder by percentage of total assets invested, with 3.29% of its assets in 186K Travere Therapeutics shares, valued at 7.11M$.

Who is the top mutual fund holder of Travere Therapeutics shares?

Delaware Small Cap Core I is the top mutual fund holder of Travere Therapeutics shares, with 4.42% of its total shares outstanding invested in 3.45M Travere Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools